Noah Stansfield

The hematology-oncology and BMT cell therapy fellow at Stanford University discussed implications of his institution’s findings on treatment-related secondary malignancies.

Among the 5 patients in the efficacy set, 4 patients ceased receiving their previous standard of care therapy.

The IND clearance constitutes the first for a xenokidney product.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, also shared his thoughts on the 75th anniversary of the organization.

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, discussed what attendees can expect at the 2025 MDA Meeting.

The company received a recommendation from the study’s IDMC to move onto enrollment for the trial’s second cohort.

The chief medical advisor of the Muscular Dystrophy Association also shared his thoughts on the 75th anniversary of the organization.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

With regard to safety, the company stated that no new safety signals have been reported.

The chief medical advisor of the Muscular Dystrophy Association discussed what attendees can expect at the 2025 MDA Meeting.

The planned phase 1 RESOLUTION study will include patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.

The company has begun the process of randomly assigning enrolled participants in the sham-controlled phase 2 REGENERATE-PD trial.

David Porter, MD, the director of cell therapy and transplant at Penn Medicine, also summed up his main message regarding the current state of the field in general.

The medical director of the Immune Effector Cell Therapy Program at UCLA discussed initial data from a phase 1/2 trial.

The company stated it expects to submit a BLA to the FDA next year.

The director of cell therapy and transplant at Penn Medicine also summed up his main message regarding the current state of the field in general.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

At 12 months of follow-up, there were no dose-limiting toxicities and no severe adverse events related to the treatment reported.

David Porter, MD, the director of cell therapy and transplant at Penn Medicine, discussed progress made and experienced gained for the field of cell therapy in autoimmune disease in 2024.

SGT-212, a dual route gene transfer therapy, is intended to be delivered both by intradentate nucleus infusion and IV infusion at the same time.

The holds are related to a GMP compliance issue at a third-party manufacturing facility.

CGTLive® took a closer look at the first-in-human clinical trial for the next-generation gene therapy.

Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg, discussed potential upcoming innovations in the field.

The director of cell therapy and transplant at Penn Medicine discussed progress made and experienced gained for the field of cell therapy for autoimmune disease in 2024.

The CRL was related inspection of a third-party manufacturer rather than any efficacy or safety concerns regarding the product itself.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.